GO:0050786 RAGE receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050786 (RAGE receptor binding) is a molecular function describing the binding of a ligand to the receptor for advanced glycation end-products (RAGE).
• RAGE is a multiligand receptor of the immunoglobulin superfamily that binds advanced glycation end-products (AGEs), S100/calgranulins, high-mobility group box 1 (HMGB1), and amyloid-beta, among others.
• Ligand binding to RAGE can trigger pro-inflammatory signaling, but binding alone is not always sufficient to induce inflammation, as shown for endotoxin-free albumin-derived AGEs.
• RAGE signaling is implicated in diabetes complications, neurodegeneration, chronic obstructive pulmonary disease (COPD), and COVID-19-associated inflammation.
• Key research methods to study RAGE receptor binding include surface plasmon resonance, isothermal titration calorimetry, co-immunoprecipitation, and CRISPR-based knockout or knock-in models.
• EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, and CRISPR library screening to dissect RAGE-ligand interactions and downstream signaling.
Description
GO:0050786, RAGE receptor binding, is a molecular function term that describes the selective interaction between a ligand and the receptor for advanced glycation end-products (RAGE). RAGE is a pattern-recognition receptor that binds structurally diverse ligands, including advanced glycation end-products (AGEs), S100/calgranulin proteins, high-mobility group box 1 (HMGB1), and amyloid-beta. This binding event is the first step in a signaling cascade that can activate NF-kB and other pro-inflammatory pathways, linking RAGE to diabetes, neurodegeneration, and chronic inflammatory diseases. Researchers study RAGE receptor binding to understand how environmental and endogenous ligands initiate pathological signaling and to develop therapeutic strategies that block these interactions.
RAGE receptor binding At A Glance
| GO ID | GO:0050786 |
|---|---|
| GO term | RAGE receptor binding |
| Ontology | molecular_function |
| Synonym | advanced glycation end-product receptor binding |
| Definition | Binding to a RAGE receptor, the receptor for advanced glycation end-products. |
| Major function | Mediates ligand recognition by RAGE, initiating downstream signaling. |
| Major ligands | AGEs, S100/calgranulins, HMGB1, amyloid-beta, and other DAMPs. |
| Associated diseases | Diabetes complications, neurodegeneration, COPD, COVID-19 inflammation. |
| Research methods | Surface plasmon resonance, ITC, co-IP, CRISPR knockout/knock-in. |
What Is GO:0050786?
According to the Gene Ontology, GO:0050786 (RAGE receptor binding) is defined as the binding to a RAGE receptor, the receptor for advanced glycation end-products. In other words, it is the molecular function of a ligand physically interacting with RAGE, a cell-surface receptor that recognizes AGEs and other damage-associated molecular patterns. This term is used to annotate gene products that directly bind to RAGE, such as AGE-modified proteins, S100 proteins, HMGB1, and amyloid-beta.
Why Is RAGE receptor binding Important in Cell Biology?
RAGE receptor binding is important because it represents the initial molecular event that triggers RAGE-mediated signaling, which is implicated in a wide range of human diseases, including diabetic complications, Alzheimer's disease, chronic obstructive pulmonary disease, and severe COVID-19. Understanding the specificity and affinity of RAGE-ligand interactions is critical for developing therapeutic inhibitors that block pathological signaling without disrupting beneficial functions. Moreover, the observation that ligand binding is not always sufficient to induce inflammatory signals highlights the need for careful mechanistic studies.
• RAGE receptor binding initiates pro-inflammatory signaling in diabetes and its complications.
• It contributes to neuroinflammation and cognitive deficits in chronic hyperglycemia.
• RAGE binding of oxidized IL-33 drives COPD epithelial pathogenesis via a ST2-independent RAGE/EGFR signaling complex.
• RAGE may act as a potential inflammatory mediator in SARS-CoV-2 infection.
• RAGE binds amyloid-beta and is implicated in Alzheimer's disease pathology.
• The binding event is a target for medicinal chemistry efforts to develop RAGE antagonists.
• Not all RAGE ligands induce inflammation upon binding, indicating context-dependent signaling.
• RAGE receptor binding is studied using recombinant proteins, cell-based assays, and animal models.
• CRISPR-based gene editing enables precise dissection of RAGE-ligand interactions.
• RAGE is a multiligand receptor, making its binding function central to diverse physiological and pathological processes.
What Happens During RAGE receptor binding?
Ligand recognition and binding
In simple terms: First, a ligand such as an AGE or S100 protein docks onto the RAGE receptor on the cell surface.
RAGE is a transmembrane receptor of the immunoglobulin superfamily that binds a broad repertoire of ligands, including advanced glycation end-products (AGEs), S100/calgranulins, HMGB1, and amyloid-beta. The binding occurs primarily through the extracellular V and C1 domains of RAGE. This interaction is the defining event for GO:0050786 and can be measured using biophysical techniques such as surface plasmon resonance.
Receptor oligomerization and signaling complex assembly
In simple terms: After binding, RAGE molecules cluster together and recruit signaling proteins inside the cell.
Ligand binding promotes RAGE oligomerization and the formation of signaling complexes that include adaptor proteins such as RIPK1 and EGFR. For example, oxidized IL-33 drives COPD epithelial pathogenesis via a ST2-independent RAGE/EGFR signaling complex. In chronic hyperglycemia, binding of RAGE and RIPK1 induces cognitive deficits in neuroinflammation.
Downstream inflammatory signaling
In simple terms: The clustered receptor then activates inflammatory pathways, such as NF-kB.
RAGE-mediated signaling activates NF-kB and other pro-inflammatory transcription factors, leading to the production of cytokines and adhesion molecules. However, binding of RAGE ligands is not always sufficient to induce inflammatory signals; endotoxin-free albumin-derived AGEs lack activity, indicating that ligand quality and context matter. This complexity underscores the need for careful experimental design when studying RAGE receptor binding.
Pathophysiological outcomes
In simple terms: Over time, this signaling can damage tissues and contribute to diseases like diabetes and neurodegeneration.
Persistent RAGE activation is linked to diabetic complications, neurodegeneration, and chronic inflammatory diseases. In type 1 diabetes, RAGE contributes to pathogenesis through interactions with AGEs and other ligands. In the brain, RAGE-RIPK1 binding under hyperglycemic conditions induces cognitive deficits. RAGE has also been proposed as a potential inflammatory mediator in SARS-CoV-2 infection.
Key Genes Involved in GO:0050786 RAGE receptor binding
The following genes and proteins are central to RAGE receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AGER | Encodes the RAGE receptor | Primary receptor for GO:0050786; target for knockout and knock-in studies. |
| HMGB1 | Ligand for RAGE | Pro-inflammatory DAMP; studied in sepsis and cancer. |
| S100A8 | Ligand for RAGE | Calgranulin involved in inflammation; binding to RAGE activates NF-kB. |
| S100A9 | Ligand for RAGE | Forms heterodimers with S100A8; implicated in autoimmune diseases. |
| S100B | Ligand for RAGE | Glial-derived protein; linked to neurodegeneration. |
| APP | Amyloid precursor protein | Source of amyloid-beta, a RAGE ligand in Alzheimer's disease. |
| IL33 | Cytokine ligand | Oxidized IL-33 binds RAGE to drive COPD pathogenesis. |
| RIPK1 | Signaling adaptor | Binds RAGE to induce neuroinflammation in hyperglycemia. |
| EGFR | Signaling receptor | Forms complex with RAGE in COPD epithelium. |
| NFKB1 | Transcription factor | Downstream mediator of RAGE signaling. |
| TNF | Cytokine | Induced by RAGE activation; amplifies inflammation. |
| IL6 | Cytokine | Produced upon RAGE signaling; biomarker of inflammation. |
| VCAM1 | Adhesion molecule | Upregulated by RAGE activation in endothelium. |
| MAPK1 | Kinase | Involved in RAGE downstream signaling. |
| AKT1 | Kinase | Mediates survival signals downstream of RAGE. |
| SRC | Kinase | Phosphorylated upon RAGE ligation. |
| JAK2 | Kinase | Participates in RAGE signaling in some cell types. |
| STAT3 | Transcription factor | Activated downstream of RAGE in inflammation. |
How Is RAGE receptor binding Regulated?
RAGE receptor binding is regulated at multiple levels. The expression of AGER (the gene encoding RAGE) is induced by NF-kB, creating a positive feedback loop that amplifies inflammation. Soluble RAGE (sRAGE) acts as a decoy receptor that competes with membrane-bound RAGE for ligands, thereby modulating binding. Additionally, post-translational modifications of ligands, such as oxidation of IL-33, can enhance or alter their affinity for RAGE. The presence of co-receptors like EGFR and RIPK1 also modulates the signaling outcome of RAGE binding. Finally, the local concentration of ligands and the cellular context determine whether binding leads to productive signaling.
RAGE receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AGER | Diabetes complications | Knockout mouse or CRISPR KO cell lines. |
| AGER | Alzheimer's disease | Knock-in of human RAGE in mouse models. |
| IL33 | COPD | Point mutation of oxidation sites in IL33. |
| RIPK1 | Neuroinflammation | Knockout of RIPK1 in neurons. |
| EGFR | COPD | Overexpression of EGFR in epithelial cells. |
Diabetes and its complications
RAGE receptor binding of AGEs is a key mechanism in the pathogenesis of diabetic complications, including nephropathy, retinopathy, and neuropathy. In type 1 diabetes, RAGE contributes to beta-cell dysfunction and inflammation. Chronic hyperglycemia promotes the formation of AGEs, which bind RAGE and activate pro-inflammatory and pro-fibrotic pathways. Targeting RAGE-ligand interactions is a therapeutic strategy for diabetes complications.
Neurodegeneration and cognitive deficits
In the brain, RAGE binds amyloid-beta and mediates its transport across the blood-brain barrier, contributing to Alzheimer's disease pathology. Binding of RAGE and RIPK1 under chronic hyperglycemia induces cognitive deficits through neuroinflammation. RAGE activation in microglia and neurons amplifies neuroinflammatory responses, making it a potential target for neurodegenerative diseases.
COPD and respiratory inflammation
Oxidized IL-33 drives COPD epithelial pathogenesis via a ST2-independent RAGE/EGFR signaling complex. This highlights the role of RAGE receptor binding in chronic airway inflammation and remodeling. RAGE ligands such as S100 proteins and HMGB1 are elevated in COPD and contribute to disease progression.
COVID-19 and inflammatory mediator
RAGE has been proposed as a potential inflammatory mediator for SARS-CoV-2 infection, as the virus may indirectly promote RAGE ligand release and activation. This suggests that RAGE receptor binding could contribute to the cytokine storm observed in severe COVID-19.
From RAGE receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RAGE abolish ligand-induced signaling? | AGER knockout cell line or mouse. |
| Does a specific point mutation in RAGE alter ligand binding? | Point mutation knock-in of AGER. |
| Can a tagged RAGE be used to track binding in live cells? | Tagged knock-in of AGER (e.g., GFP). |
| Does overexpression of RAGE enhance sensitivity to AGEs? | RAGE overexpression cell model. |
| Which genes modulate RAGE receptor binding? | CRISPR library screening. |
| What is the affinity of a new ligand for RAGE? | Surface plasmon resonance with recombinant RAGE. |
How to Study the RAGE receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | Characterizing RAGE-ligand interactions. |
| Isothermal titration calorimetry | Thermodynamics of binding | Quantifying enthalpy and entropy of RAGE binding. |
| Co-immunoprecipitation | Protein-protein interactions | Detecting RAGE-ligand or RAGE-adaptor complexes. |
| NF-kB reporter assay | Transcriptional activation | Assessing downstream signaling after RAGE binding. |
| ELISA | Cytokine secretion | Measuring inflammatory response to RAGE ligands. |
| Western blot | Protein phosphorylation | Detecting activation of MAPK or AKT pathways. |
| CRISPR knockout | Gene function | Determining if a gene is required for RAGE binding. |
| CRISPR library screen | Genome-wide modifiers | Identifying novel regulators of RAGE signaling. |
Biophysical binding assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are used to measure the affinity and kinetics of RAGE-ligand interactions. These methods provide quantitative data on binding constants and are essential for characterizing GO:0050786. They can be performed with recombinant RAGE extracellular domains and purified ligands.
Cell-based signaling assays
Cell-based assays such as NF-kB reporter assays, cytokine ELISAs, and Western blotting for phospho-ERK or phospho-p65 are used to assess downstream signaling after RAGE binding. These assays help determine whether binding leads to functional activation, as not all ligands induce inflammation.
Co-immunoprecipitation and proximity ligation
Co-immunoprecipitation (co-IP) and proximity ligation assays (PLA) can detect the interaction between RAGE and its ligands or signaling partners in cell lysates or intact cells. These methods are useful for studying complex formation, such as RAGE-RIPK1 or RAGE-EGFR.
CRISPR-based genetic screens
CRISPR knockout and activation screens can identify genes that regulate RAGE receptor binding and downstream signaling. Libraries targeting the human genome can be used to discover novel modulators of RAGE-ligand interactions, providing unbiased insights into the pathway.
How CRISPR Can Be Used to Study GO:0050786 RAGE receptor binding
Knockout
CRISPR knockout of AGER or its ligands (e.g., HMGB1, S100A8) can abolish RAGE receptor binding and downstream signaling, providing causal evidence for the role of specific genes. Knockout cell lines are valuable for validating drug targets and understanding disease mechanisms.
Point Mutation
Point mutations can be introduced into the RAGE ligand-binding domain or into ligand genes to dissect the structural determinants of binding. For example, mutating oxidation sites in IL-33 can prevent its interaction with RAGE and its pathogenic effects in COPD.
Knock-in
Knock-in of tagged RAGE (e.g., GFP or HA) allows real-time tracking of receptor localization and binding in live cells. Knock-in of human RAGE into mouse models can humanize the receptor for preclinical studies.
Overexpression
Overexpression of RAGE or its ligands can sensitize cells to activation and amplify signaling, useful for studying dose-dependent effects and for screening inhibitors. Overexpression models are also used to study the contribution of RAGE to cancer and inflammation.
How EDITGENE Supports RAGE receptor binding Research
Researchers studying RAGE receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, signaling, or disease pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional validation.
Contact EDITGENE today to design your custom CRISPR model for RAGE receptor binding research.
Frequently Asked Questions About RAGE receptor binding
What is GO:0050786?
GO:0050786 is the Gene Ontology molecular function term for RAGE receptor binding, defined as binding to the receptor for advanced glycation end-products.
What is RAGE receptor binding?
RAGE receptor binding is the physical interaction between a ligand (such as AGEs, S100 proteins, or HMGB1) and the RAGE receptor, initiating downstream signaling.
What genes are involved in RAGE receptor binding?
Key genes include AGER (encoding RAGE), HMGB1, S100A8, S100A9, S100B, APP, IL33, RIPK1, and EGFR.
What diseases are associated with RAGE receptor binding?
RAGE receptor binding is implicated in diabetes complications, Alzheimer's disease, COPD, and COVID-19 inflammation.
How can I study RAGE receptor binding?
You can use surface plasmon resonance, co-immunoprecipitation, cell-based signaling assays, and CRISPR knockout models.
What are the ligands of RAGE?
RAGE binds advanced glycation end-products (AGEs), S100/calgranulins, HMGB1, amyloid-beta, and oxidized IL-33.
Does RAGE binding always cause inflammation?
No, binding of RAGE ligands is not always sufficient to induce inflammatory signals; endotoxin-free albumin-derived AGEs lack activity.
What is the role of RAGE in diabetes?
RAGE binding of AGEs contributes to diabetic complications by activating pro-inflammatory and pro-fibrotic pathways.
Can CRISPR be used to study RAGE receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect RAGE-ligand interactions.
What services does EDITGENE offer for RAGE research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, library screening, and bioinformatics services.
Conclusion
GO:0050786 (RAGE receptor binding) is a critical molecular function that mediates the interaction between RAGE and diverse ligands, triggering signaling pathways involved in inflammation, diabetes, neurodegeneration, and respiratory diseases. Understanding the structural and functional basis of this binding is essential for developing targeted therapies. EDITGENE offers comprehensive CRISPR-based solutions to study RAGE receptor binding and its role in disease.
References
- 1. Strickson S et al.. 2023. Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex.. Eur Respir J 62(3) PMID: 37442582
- 2. Rouhiainen A et al.. 2013. RAGE-mediated cell signaling.. Methods Mol Biol 963:239-63 PMID: 23296615
- 3. Zhou X et al.. 2024. Binding of RAGE and RIPK1 induces cognitive deficits in chronic hyperglycemia-derived neuroinflammation.. CNS Neurosci Ther 30(3):e14449 PMID: 37665158
- 4. Valencia JV et al.. 2004. Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products.. Diabetologia 47(5):844-52 PMID: 15127201
- 5. Bongarzone S et al.. 2017. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.. J Med Chem 60(17):7213-7232 PMID: 28482155
- 6. Kerkeni M et al.. 2020. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?. Med Hypotheses 144:109950 PMID: 32531537
- 7. Bierhaus A et al.. 2005. Understanding RAGE, the receptor for advanced glycation end products.. J Mol Med (Berl) 83(11):876-86 PMID: 16133426
- 8. Leung SS et al.. 2016. Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.. Curr Diab Rep 16(10):100 PMID: 27612847
